Synopsis: Brokerages remain positive on Cipla’s long-term outlook despite weak Q1 FY27 margins, with US product launches and growth in the US business seen as the key drivers ahead.
The article outline the global brokerage stance on this company, which is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs.
With a market capitalization of Rs 1,14,407 crore, Cipla Ltd’s share currently trading at Rs 1,416 per share, up by 1.16 percent from previous close. The share of the company gave a return of 50 percent over the last five year.
Brokerage’s View
Nomura on Cipla
Nomura has maintained its ‘Buy’ rating on Cipla with a target price of Rs 1,510. The brokerage believes the company’s earnings could improve over the coming quarters, supported by high-value product launches in the US and a recovery in margins.
Margin Misses Estimates
Cipla’s Q1 FY27 EBITDA margin came in below Nomura’s expectations by 156 basis points. Despite the weaker quarter, the brokerage said the company has kept its FY27 EBITDA margin guidance unchanged at 18.5 percent to 20 percent, showing confidence in its performance for the rest of the year.
US Launches Key for Recovery
Nomura believes margin recovery will largely depend on the success of high-value product launches in the US market. It highlighted generic versions of Symbicort (gSymbicort) and Gattex (gGattex) as key products that could support earnings and improve profitability in the coming quarters.
Valuation Remains Premium
The brokerage also noted that Cipla’s stock is currently trading at around 27 times its estimated March 2027 earnings per share of Rs 52.2. This suggests investors are expecting better earnings growth, making the upcoming US launches important for future performance.
JPMorgan on Cipla
JPMorgan has maintained its ‘Overweight’ rating on Cipla with a target price of Rs 1,600. The brokerage remains positive on the company’s growth outlook, supported by its US product pipeline, operating leverage, and potential regulatory approvals in the coming quarters.
Q1 Margins Below Estimates
JPMorgan said Cipla’s Q1 FY27 revenue was broadly in line with expectations, but the EBITDA margin missed its estimate by 75 basis points. The brokerage noted that the weaker margin was the main disappointment in an otherwise stable quarterly performance.
Guidance Remains Unchanged
Management said the Q1 margin should not be seen as the normal run rate and retained its FY27 guidance. JPMorgan believes this reflects the company’s confidence in improving profitability over the remaining quarters of the financial year.
Focus on US Pipeline
The brokerage remains positive on Cipla’s US product launch pipeline and the benefits of operating leverage. It said key near-term triggers include new product approvals and the outcome of the re-inspection of the company’s Indore manufacturing plant.
Morgan Stanley on Cipla
Morgan Stanley has maintained its ‘Underweight’ rating on Cipla with a target price of Rs 1,218. While the brokerage expects the US business to improve in H2 FY27, it remains cautious and believes sustained growth in the US market will be key for the stock.
Q1 Performance In Line
The brokerage said Cipla’s Q1 FY27 performance was broadly in line with expectations. While the overall results were steady, EBITDA declined during the quarter due to a few temporary factors that affected profitability.
Margins Impacted by One-Off Factors
According to the brokerage, EBITDA was affected by the loss of Revlimid sales, war-related costs, and higher spending on pre-launch activities. These factors weighed on margins, although they are not expected to remain at the same level.
US Business Remains Key
The brokerage said achieving the US$1 billion sales target in the US market remains the biggest growth driver for Cipla. It expects the US business revenue run rate to improve from the second half of FY27 as new products contribute to sales.
About the Company
Cipla is a leading Indian multinational pharmaceutical company headquartered in Mumbai, renowned for manufacturing affordable generic drugs, respiratory medications, and active pharmaceutical ingredients (APIs). Founded in 1935, the company operates in over 80 markets worldwide and ranks as the third-largest drug producer in India.
Financial highlight
Revenue grew by 2 percent YoY to Rs 7,119 crore in Q1 FY27 from Rs 6,957 crore in Q1 FY26, while EBITDA declined by 33 percent to Rs 1,192 crore in Q1 FY27 from Rs 1,778 crore in Q1 FY26. Accompanied by a net profit decrease of 39 percent to Rs 786 crore in Q1 FY27 from Rs 1,292 crore in Q1 FY26, resulting in an EPS decrease of 39 percent to Rs 9.77 per share in Q1 FY27 from Rs 16.06 per share in Q1 FY26.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
